Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. Unfortunately, this disease is often diagnosed at a late incurable stage, with less than 5% of patients surviving 5 years. Antiangiogenic therapy has not been well studied in this disease. The first specific aim of this study will help define the role of treatment with angiogenesis inhibitors in a mouse model of pancreatic cancer that closely resembles human disease.
In specific aim 1 I will look at different combinations of antiangiogenic agents. Adenoassociated virus will be used to deliver novel antiangiogenic agents. Combinations of antiangiogenic agents and the chemotherapeutic agent, Gemcitabine, will also be tested. Preliminary data points to the importance of apoptosis during antiangiogenic therapy with recombinant Type I repeats of TSP-1 (TSR) in this model of pancreatic cancer. Therefore, in specific aim 2 the molecular mechanisms of the signal transduction pathways that are involved in mediating apoptosis by TSP-1 will be analyzed. Completion of this mentored project will allow me to gain in-depth expertise in areas such as novel delivery mechanisms such as gene therapy, detailed analysis of apoptotic pathways focusing on endothelial and tumor cell responses to antiangiogenic agents. This unique combination will allow me to complete the first phase of my career development and progress on to independent research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA088965-04
Application #
6924633
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lohrey, Nancy
Project Start
2002-08-07
Project End
2007-07-31
Budget Start
2005-08-17
Budget End
2006-07-31
Support Year
4
Fiscal Year
2005
Total Cost
$130,329
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Mekel, Michal; Nucera, Carmelo; Hodin, Richard A et al. (2010) Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg 200:136-43
Zhang, Xuefeng; Kazerounian, Shideh; Duquette, Mark et al. (2009) Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 23:3368-76
Ren, Bin; Song, Keli; Parangi, Sareh et al. (2009) A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 69:3856-65
Zhang, Xuefeng; Xu, Jianfeng; Lawler, Jack et al. (2007) Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res 13:3968-76
Zhang, Xuefeng; Connolly, Caitlin; Duquette, Mark et al. (2007) Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Lett 247:143-9
Zhang, Xuefeng; Galardi, Eric; Duquette, Mark et al. (2005) Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res 11:5622-30
Ren, Bin; Wang, Yuan; Ndebele, Kenneth et al. (2005) Multiple signaling is involved in endostatin-mediated apoptosis in ECV 304 endothelial cells. Front Biosci 10:1089-97
Zhang, Xuefeng; Galardi, Eric; Duquette, Mark et al. (2005) Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res 11:2337-44